Chutes & Ladders—Califf returns to FDA after narrow Senate confirmationnews2022-02-16T19:14:18+00:00February 16th, 2022|FierceBiotech|
NIAID vaccine R&D director who collaborated with Moderna on COVID-19 vaccine to retirenews2022-02-16T17:43:53+00:00February 16th, 2022|FierceBiotech|
Gilead comes back around on Hookipa HIV partnership, signing away $15M upfront and more down the linenews2022-02-16T14:49:10+00:00February 16th, 2022|FierceBiotech|
Sage, Biogen score on phase 3 depression trial, but we still don’t know about durabilitynews2022-02-16T14:27:57+00:00February 16th, 2022|FierceBiotech|
Mirati’s ‘very big’ KRAS drug gets December decision date, further extending Lumakras’ first-mover statusnews2022-02-16T13:52:57+00:00February 16th, 2022|FierceBiotech|
After a year as Merck KGaA healthcare CEO, Guenter reflects on I-O bispecific flop, spots new multiple sclerosis strategynews2022-02-16T11:03:04+00:00February 16th, 2022|FierceBiotech|
Third Harmonic Bio raises $105M in series B to push hives treatment through phase 1bnews2022-02-15T21:24:42+00:00February 15th, 2022|FierceBiotech|
Single-asset Equillium buys Bioniz for up to $329M, adding 3 drugs to its pipelinenews2022-02-15T19:54:32+00:00February 15th, 2022|FierceBiotech|
Electra, one of 2 Star biotechs, snags $84M to apply brakes to ‘immune system haywire’news2022-02-15T18:53:17+00:00February 15th, 2022|FierceBiotech|
Cytokinetics drug fails late-stage trial testing exercise capacity, as FDA considers nod in heart failurenews2022-02-15T17:59:03+00:00February 15th, 2022|FierceBiotech|
